Investor Presentaiton
22
Investor presentation
Full year 2022
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Novo NordiskⓇ
Diabetes care
DKK
billion
1000
Obesity care
DKK
billion
#1
50%
28
Haemophilia
DKK
billion
#1
100%
100
#3
50%
24
800
40%
80%
80
40%
20
600
30%
16
60
60%
60
60
30%
12
400
20%
40%
40
40
20%
8
200
CAGR¹ value: 13.8%
10%
CAGR² value: 63.5%
20%
20
4
20
10%
CAGR³ value: 3.8%
0
Nov
2017
Market value
NN value market share (RHS)
Global market position
0%
0
Nov
2022
Nov
2020
0%
0
Nov
2022
FY
2018
0%
FY
2021
Market value
Market value
NN value market share (RHS)
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 3-year period; RHS: Right-hand side; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, Recombinant and plasma derived products;
Source: Company reports for haemophilia market; IQVIA MAT, Nov 2022; Note: Diabetes and Obesity care market values are based on list prices in the US.
NN: Novo Nordisk.
NN value market share (RHS)
Global market positionView entire presentation